Ildefonso Rodriguez-Rivera

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

A. Zelenetz, M. Perales, S. Devlin, 2020, Blood advances.

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

G. Salles, A. Zelenetz, S. Horwitz, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood advances.

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2020 .

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2020 .

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

V. Seshan, G. Salles, A. Zelenetz, 2022, Blood Cancer Journal.

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

A. Zelenetz, S. Horwitz, A. Dogan, 2020 .